Page 77 - Read Online

Lee et al. J Cancer Metastasis Treat 2021;7:27 https://dx.doi.org/10.20517/2394-4722.2021.58 Page 17 of 18

2013;27:504-13. DOI PubMed PMC
115. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705. DOI PubMed
116. Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain
family. Cell 2012;149:214-31. DOI PubMed PMC
117. Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad
Sci U S A 2011;108:16669-74. DOI PubMed PMC
118. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-
17. DOI PubMed PMC
119. Bian B, Bigonnet M, Gayet O, et al. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to
the BET bromodomain inhibitor JQ 1: implications for individualized medicine efforts. EMBO Mol Med 2017;9:482-97. DOI
PubMed PMC
120. Li N, Yang L, Qi XK, et al. BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells
partially through repressing c-Myc. Cell Death Dis 2018;9:761. DOI PubMed PMC
121. Shao Q, Kannan A, Lin Z, Stack BC, Suen JY, Gao L. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in
vivo. Cancer Res 2014;74:7090-102. DOI PubMed PMC
122. Baratta MG, Schinzel AC, Zwang Y, et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a
potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A 2015;112:232-7. DOI PubMed PMC
123. Gao X, Wu X, Zhang X, et al. Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer. Biochem
Biophys Res Commun 2016;469:679-85. DOI PubMed
124. Mio C, Conzatti K, Baldan F, et al. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells. Oncol
Rep 2018;39:582-8. DOI PubMed
125. Zhu X, Enomoto K, Zhao L, et al. Bromodomain and extraterminal protein inhibitor JQ1 suppresses thyroid tumor growth in a mouse
model. Clin Cancer Res 2017;23:430-40. DOI PubMed PMC
126. McFadden DG, Vernon A, Santiago PM, et al. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse
model of papillary thyroid cancer. Proc Natl Acad Sci U S A 2014;111:E1600-9. DOI PubMed PMC
127. Zaballos MA, Santisteban P. Key signaling pathways in thyroid cancer. J Endocrinol 2017;235:R43-61. DOI PubMed
128. Naoum GE, Morkos M, Kim B, Arafat W. Novel targeted therapies and immunotherapy for advanced thyroid cancers. Mol Cancer
2018;17:51. DOI PubMed PMC
129. Zhu X, Holmsen E, Park S, Willingham MC, Qi J, Cheng SY. Synergistic effects of BET and MEK inhibitors promote regression of
anaplastic thyroid tumors. Oncotarget 2018;9:35408-21. DOI PubMed PMC
130. Ozer HG, El-Gamal D, Powell B, et al. BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and
reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor. Cancer Discov 2018;8:458-77. DOI PubMed PMC
131. Barrett SD, Bridges AJ, Dudley DT, et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg
Med Chem Lett 2008;18:6501-4. DOI PubMed
132. Wang L, Lonard DM, O’Malley BW. The role of steroid receptor coactivators in hormone dependent cancers and their potential as
therapeutic targets. Horm Cancer 2016;7:229-35. DOI PubMed PMC
133. Yao TP, Ku G, Zhou N, Scully R, Livingston DM. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc
Natl Acad Sci U S A 1996;93:10626-31. DOI PubMed PMC
134. Anafi M, Yang YF, Barlev NA, et al. GCN5 and ADA adaptor proteins regulate triiodothyronine/GRIP1 and SRC-1 coactivator-
dependent gene activation by the human thyroid hormone receptor. Mol Endocrinol 2000;14:718-32. DOI PubMed
135. Brown K, Chen Y, Underhill TM, Mymryk JS, Torchia J. The coactivator p/CIP/SRC-3 facilitates retinoic acid receptor signaling via
recruitment of GCN5. J Biol Chem 2003;278:39402-12. DOI PubMed
136. Koh SS, Chen D, Lee YH, Stallcup MR. Synergistic enhancement of nuclear receptor function by p160 coactivators and two
coactivators with protein methyltransferase activities. J Biol Chem 2001;276:1089-98. DOI PubMed
137. Spencer TE, Jenster G, Burcin MM, et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 1997;389:194-8. DOI
PubMed
138. Zhang H, Yi X, Sun X, et al. Differential gene regulation by the SRC family of coactivators. Genes Dev 2004;18:1753-65. DOI
PubMed PMC
139. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science
1997;277:965-8. DOI PubMed
140. Yan J, Tsai SY, Tsai MJ. SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharmacol Sin 2006;27:387-94. DOI
PubMed
141. Xu J, Wu RC, O'Malley BW. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev
Cancer 2009;9:615-30. DOI PubMed PMC
142. Torres-Arzayus MI, Font de Mora J, Yuan J, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice
define AIB1 as an oncogene. Cancer Cell 2004;6:263-74. DOI PubMed
143. Ying H, Willingham M, Cheng S. The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer.
Oncogene 2008;27:823-30. DOI PubMed
144. Lonard DM, O'malley BW. Nuclear receptor coregulators: modulators of pathology and therapeutic targets. Nat Rev Endocrinol
2012;8:598-604. DOI PubMed PMC
145. Song X, Chen J, Zhao M, et al. Development of potent small-molecule inhibitors to drug the undruggable steroid receptor